BCL2 and cancer: In combination with gamitrinib, LXR623 synergistically reduced the proliferation of cancer cells by promoting apoptosis via upregulating Bax and downregulating Bcl-2, and this combination even inhibited the expression of Tumor Necrosis Factor Receptor-associated Protein 1.